Chromosome 3 Aneuploidy in Squamous Cell Carcinoma and its Impact on Key Cancer Pathways
Official title: Elucidating the Consequences of Chromosome 3 Arm Aneuploidies in Squamous Cell Carcinoma
Funded at Columbia University Health Sciences · NIH-11398272 · Data updated 2026-11-12
This grant studies how losing or gaining parts of chromosome 3 drives squamous cell cancers and alters important cell signaling and growth pathways.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 21, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $365,017 |
| NIH project number | 5R01CA273723-04 |
| Project ID | NIH-11398272 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with squamous cell carcinomas (lung, esophagus, head and neck) who may benefit from future therapies targeting chromosome 3 arm aneuploidy.
✕Less likely to help
This line of work is preclinical and may not directly benefit patients in the immediate term.
What this research studies
Researchers will use engineered human lung epithelial cells to model chromosome 3 arm losses and gains, then examine how these changes affect lipid/PI3K signaling, hypoxia response, and how squamous differentiation and tumor formation occur. The work aims to connect these chromosomal changes to two major pathways that could be targeted in patients with squamous cell carcinomas of the lung, esophagus, or head and neck. Expect a combination of cell biology, signaling analysis, and cancer-relevant assays to map how 3p loss and 3q gain influence tumor behavior. The findings could point toward new therapeutic strategies for SCCs with this distinct aneuploidy profile.
Why it matters
Potential benefit: If successful, the research could identify new targets and strategies for treating squamous cell carcinomas linked to chromosome 3 aneuploidy.
How similar studies have gone: Preliminary data and prior work with the chromosome 3p deletion and 3q gain models suggest this approach can reveal meaningful biological insights.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Taylor, Alison M. — Columbia University Health Sciences
- Study coordinator: Taylor, Alison M.
Related research
Other NIH-funded projects on the same topics.
-
Novel idea: Epstein-Barr virus and eye cancer in people living with HIV in Zimbabwe
A study explores whether Epstein-Barr virus could cause a type of eye cancer in people living with HIV in Zimbabwe.
-
Oral cancer recurrence predictor using tumor microbes and gene activity
This NIH grant explores how bacteria and immune signals inside oral cancer tumors relate to whether the cancer comes back, with the aim of making a practical risk predictor for patients.
-
Data-driven classification of aggressive tissue traits to predict cancer outcomes in HPV-negative head and neck cancer
A clinician-science grant uses data science and AI to identify tissue patterns in HPV-negative head and neck cancer that may predict how long patients stay cancer-free.
-
Targeting PIPKIγi5 to boost immune responses against head and neck cancer
A study to see if blocking a specific enzyme, PIPKIγi5, can make head and neck cancer more visible to the immune system and more responsive to existing immunotherapies.
-
Targeted approaches for lung squamous cell carcinoma with key gene changes
A study at a major university is exploring new targets in lung squamous cell carcinoma to help people with this cancer find better treatments.
-
Baculovirus-based therapy to treat head and neck cancer with a gentle, minimally invasive approach
A new, minimally invasive approach using baculovirus-delivered CRISPR gene editing aims to treat head and neck squamous cell carcinoma while aiming to preserve essential tissues.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.